Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Published:2017-03-23 Issue:8 Volume:143 Page:1543-1554
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Rajala Hanna L. M.,Missiry Mohamed El,Ruusila Anniina,Koskenvesa Perttu,Brümmendorf Tim H.,Gjertsen Bjorn T.,Janssen Jeroen,Lotfi Kourosh,Markevärn Berit,Olsson-Strömberg Ulla,Stenke Leif,Stentoft Jesper,Richter Johan,Hjorth-Hansen Henrik,Kreutzman Anna,Mustjoki Satu

Funder

Novartis Pharma

Ariad Pharmaceuticals

Pfizer

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s00432-017-2378-6/fulltext.html

Reference27 articles.

1. Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884. doi: 10.1182/blood-2013-05-501569

2. Bantscheff M, Eberhard D, Abraham Y et al (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25:1035–1044. doi: 10.1038/nbt1328

3. Caldwell CW, Patterson WP (1987) Relationship between T200 antigen expression and stages of B cell differentiation in resurgent hyperplasia of bone marrow. Blood 70:1165–1172

4. Carulli G, Cannizzo E, Ottaviano V et al (2010) Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. Leuk Res 34:1336–1339. doi: 10.1016/j.leukres.2010.01.012

5. Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia. N Engl J Med 355:2408–2417. doi: 10.1056/NEJMoa062867

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Depth of the Molecular Response in Patients with Chronic Myeloid Leukemia Correlates with Changes in Humoral Immunity;Journal of Clinical Medicine;2024-04-18

2. Management of chronic myelogenous leukemia with COVID-19 and hepatitis B;Frontiers in Oncology;2023-08-03

3. Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways;OncoTargets and Therapy;2022-10

4. IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia;Journal of Clinical Investigation;2022-09-01

5. Tumor progression with thyrotoxicosis on differentiated thyroid carcinoma due to thyrotropin receptor stimulation: is tyrosine kinase inhibitors the cause of thyroid stimulating hormone receptor antibody positivity?;Annals of Palliative Medicine;2022-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3